Multiple sclerosis treatment has been transformed by 20+ approved disease-modifying therapies (DMTs), with high-efficacy treatments like ocrelizumab, ofatumumab, and natalizumab fundamentally changing relapsing-remitting MS outcomes. Research now focuses on progressive MS (where treatment options remain limited), remyelination strategies, and treatment optimization. For patients with MS, clinical trials for multiple sclerosis offer access to next-generation DMTs, investigational remyelination approaches, and emerging disease-modifying strategies. This guide covers how to find MS trials, active research areas in 2026, eligibility considerations, and resources.
Categories of MS trials
Active MS trials in 2026 include:
BTK inhibitors: Bruton’s tyrosine kinase inhibitors (tolebrutinib, evobrutinib, fenebrutinib) target both peripheral B cells and CNS-resident immune cells. Multiple Phase 3 trials in relapsing and progressive MS.
Next-generation B-cell depleting therapies: More potent or selective anti-CD20 therapies, anti-CD19 approaches.
Remyelination strategies: Trials testing whether oligodendrocyte progenitor cell stimulation can repair existing damage. Clemastine, opicinumab, and emerging mechanisms.
Progressive MS specifically: Most MS treatments work primarily in relapsing disease. Trials in primary progressive and secondary progressive MS test whether neurodegeneration can be slowed.
Stem cell approaches: Autologous hematopoietic stem cell transplantation (AHSCT) for highly active MS; emerging trials in expanded populations.
Symptomatic therapies: Trials for fatigue, walking speed, cognitive impairment, spasticity.
Where to find MS trials
Resources:
- ClinicalTrials.gov
- National MS Society — research and trial resources
- Multiple Sclerosis Association of America — patient resources
- Major academic MS centers (Cleveland Clinic, Johns Hopkins, UCSF, etc.)
- Consortium of MS Centers — academic MS research network
Disease subtype considerations
MS trials are typically subtype-specific:
Relapsing-remitting MS (RRMS): Most active trial area. New DMTs typically tested first in RRMS.
Secondary progressive MS (SPMS): Patients who started with RRMS but transitioned to progressive course. Limited approved options; active trial area.
Primary progressive MS (PPMS): Progressive from onset. Ocrelizumab is approved; other trials seeking additional options.
Active vs non-active progressive disease: Some trials specifically enroll progressive MS patients with active disease (relapses or new MRI lesions); others enroll non-active progressive disease.
Typical eligibility for MS trials
Common inclusion criteria:
- Diagnosis of MS meeting McDonald criteria
- Disease duration in specific range
- EDSS score in specific range (varies by trial)
- Specific disease activity (relapses, new MRI lesions for some trials)
- Adequate organ function
- Stable medications for specified period
Common exclusion criteria:
- Other neurological diseases
- Significant cardiovascular disease
- Active infection
- Pregnancy
- Specific prior therapy that disqualifies (varies by trial)
- Significant disability beyond trial range (e.g., EDSS above 6.5 or 7.0)
What participation involves
MS trials typically involve:
- Baseline workup including detailed neurological exam, MRI brain and spine, sometimes labs and ECG
- Treatment with experimental therapy (varies by mechanism)
- Regular study visits every 3-6 months with neurological exam, EDSS scoring, MS Functional Composite
- MRI imaging at multiple timepoints to assess lesions
- Patient-reported outcomes for symptoms, fatigue, quality of life
- Long-term follow-up
Trials in relapsing MS often last 2-3 years; progressive MS trials may run 3-5 years to detect changes in disability progression.
Frequently Asked Questions
Are progressive MS trials available?
Yes. BTK inhibitors and other emerging mechanisms are being tested in primary and secondary progressive MS. Limited approved options make trial participation more relevant.
Do I need to be off my current MS medication to enroll?
Often yes, with washout periods that vary by drug. Specific medication washout requirements affect timing of enrollment.
What’s autologous stem cell transplantation for MS?
AHSCT involves chemotherapy followed by reinfusion of the patient’s own stem cells, essentially “resetting” the immune system. Studies show high efficacy in highly active relapsing MS but with significant short-term risk. Trials continue to refine indications.
Are trials for pediatric MS available?
Limited but increasing. Most disease-modifying trials are in adults. Pediatric MS clinical research is growing.
Should I participate in a trial vs starting an approved DMT?
Discuss with your neurologist. Approved DMTs have established efficacy and safety; trials may offer access to next-generation therapies but with uncertainty. The right choice depends on disease activity, prior treatment, and risk tolerance.
The bottom line on MS trials
MS trials are active across all subtypes with particular emphasis on BTK inhibitors, remyelination strategies, and progressive disease therapies. Discuss with your neurologist as part of treatment planning. The National MS Society and academic MS centers provide extensive resources for finding relevant trials.